Annual CFO
-$23.91 M
+$37.69 M+61.18%
31 December 2023
Summary:
Seelos Therapeutics annual cash flow from operations is currently -$23.91 million, with the most recent change of +$37.69 million (+61.18%) on 31 December 2023. During the last 3 years, it has fallen by -$3.00 million (-14.34%). SEEL annual CFO is now -781.55% below its all-time high of -$2.71 million, reached on 31 December 2008.SEEL Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$972.00 K
+$3.67 M+79.06%
30 June 2024
Summary:
Seelos Therapeutics quarterly cash flow from operations is currently -$972.00 thousand, with the most recent change of +$3.67 million (+79.06%) on 30 June 2024. Over the past year, it has increased by +$4.78 million (+83.09%). SEEL quarterly CFO is now -136.21% below its all-time high of $2.68 million, reached on 30 September 2018.SEEL Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$13.27 M
+$4.93 M+27.09%
30 June 2024
Summary:
Seelos Therapeutics TTM cash flow from operations is currently -$13.27 million, with the most recent change of +$4.93 million (+27.09%) on 30 June 2024. Over the past year, it has increased by +$21.82 million (+62.17%). SEEL TTM CFO is now -1781.32% below its all-time high of $789.50 thousand, reached on 30 September 2009.SEEL TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SEEL Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.2% | +83.1% | +62.2% |
| 3 y3 years | -14.3% | +90.8% | +60.9% |
| 5 y5 years | -194.2% | +66.6% | +37.2% |
SEEL Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -14.3% | +61.2% | at high | +95.2% | at high | +80.1% |
| 5 y | 5 years | -194.2% | +61.2% | at high | +95.2% | at high | +80.1% |
| alltime | all time | -781.5% | +61.2% | -136.2% | +95.2% | -1781.3% | +80.1% |
Seelos Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$972.00 K(-79.1%) | -$13.27 M(-27.1%) |
| Mar 2024 | - | -$4.64 M(+142.9%) | -$18.21 M(-23.9%) |
| Dec 2023 | -$23.91 M(-61.2%) | -$1.91 M(-66.8%) | -$23.91 M(-31.9%) |
| Sept 2023 | - | -$5.75 M(-2.6%) | -$35.09 M(-13.2%) |
| June 2023 | - | -$5.90 M(-42.9%) | -$40.42 M(-26.4%) |
| Mar 2023 | - | -$10.35 M(-20.9%) | -$54.91 M(-10.9%) |
| Dec 2022 | -$61.60 M(+25.7%) | -$13.09 M(+18.2%) | -$61.60 M(-7.9%) |
| Sept 2022 | - | -$11.07 M(-45.7%) | -$66.85 M(+0.9%) |
| June 2022 | - | -$20.39 M(+19.7%) | -$66.29 M(+21.0%) |
| Mar 2022 | - | -$17.05 M(-7.1%) | -$54.79 M(+11.8%) |
| Dec 2021 | -$48.99 M(+134.3%) | -$18.34 M(+74.5%) | -$48.99 M(+44.2%) |
| Sept 2021 | - | -$10.51 M(+18.2%) | -$33.98 M(+22.9%) |
| June 2021 | - | -$8.89 M(-21.0%) | -$27.66 M(+7.4%) |
| Mar 2021 | - | -$11.25 M(+238.0%) | -$25.74 M(+23.1%) |
| Dec 2020 | -$20.91 M(+8.3%) | -$3.33 M(-20.4%) | -$20.91 M(-7.9%) |
| Sept 2020 | - | -$4.18 M(-40.1%) | -$22.70 M(+5.9%) |
| June 2020 | - | -$6.98 M(+8.7%) | -$21.43 M(+20.5%) |
| Mar 2020 | - | -$6.42 M(+25.5%) | -$17.79 M(-7.9%) |
| Dec 2019 | -$19.30 M(+137.5%) | -$5.12 M(+75.9%) | -$19.30 M(-8.6%) |
| Sept 2019 | - | -$2.91 M(-12.8%) | -$21.13 M(+36.0%) |
| June 2019 | - | -$3.34 M(-58.0%) | -$15.54 M(+9.9%) |
| Mar 2019 | - | -$7.94 M(+14.3%) | -$14.14 M(+74.0%) |
| Dec 2018 | -$8.13 M(-22.3%) | -$6.95 M(-358.8%) | -$8.13 M(+122.3%) |
| Sept 2018 | - | $2.68 M(-238.4%) | -$3.66 M(-61.0%) |
| June 2018 | - | -$1.94 M(+0.6%) | -$9.37 M(-3.4%) |
| Mar 2018 | - | -$1.93 M(-22.0%) | -$9.70 M(-7.3%) |
| Dec 2017 | -$10.47 M(-19.9%) | -$2.47 M(-18.3%) | -$10.47 M(-2.2%) |
| Sept 2017 | - | -$3.03 M(+33.5%) | -$10.70 M(+25.4%) |
| June 2017 | - | -$2.27 M(-15.8%) | -$8.53 M(-10.2%) |
| Mar 2017 | - | -$2.70 M(-0.3%) | -$9.50 M(-27.3%) |
| Dec 2016 | -$13.07 M(-42.3%) | -$2.71 M(+214.2%) | -$13.07 M(+12.0%) |
| Sept 2016 | - | -$861.00 K(-73.4%) | -$11.67 M(-32.9%) |
| June 2016 | - | -$3.24 M(-48.3%) | -$17.41 M(-23.6%) |
| Mar 2016 | - | -$6.26 M(+378.2%) | -$22.78 M(+0.6%) |
| Dec 2015 | -$22.64 M(+25.7%) | -$1.31 M(-80.1%) | -$22.64 M(-25.6%) |
| Sept 2015 | - | -$6.59 M(-23.4%) | -$30.45 M(+9.0%) |
| June 2015 | - | -$8.61 M(+40.5%) | -$27.93 M(+16.6%) |
| Mar 2015 | - | -$6.13 M(-32.8%) | -$23.95 M(+32.9%) |
| Dec 2014 | -$18.02 M(+19.6%) | -$9.12 M(+123.6%) | -$18.02 M(+128.3%) |
| Sept 2014 | - | -$4.08 M(-11.9%) | -$7.89 M(-1.6%) |
| June 2014 | - | -$4.63 M(+2310.4%) | -$8.02 M(-5.5%) |
| Mar 2014 | - | -$192.00 K(-119.1%) | -$8.48 M(-43.7%) |
| Dec 2013 | -$15.06 M(+4.7%) | $1.01 M(-123.9%) | -$15.06 M(-19.9%) |
| Sept 2013 | - | -$4.21 M(-17.4%) | -$18.81 M(+7.5%) |
| June 2013 | - | -$5.09 M(-24.8%) | -$17.50 M(+9.4%) |
| Mar 2013 | - | -$6.77 M(+147.6%) | -$15.99 M(+11.2%) |
| Dec 2012 | -$14.38 M(+47.9%) | -$2.73 M(-5.6%) | -$14.38 M(+2.2%) |
| Sept 2012 | - | -$2.90 M(-19.3%) | -$14.07 M(+0.8%) |
| June 2012 | - | -$3.59 M(-30.4%) | -$13.96 M(+12.2%) |
| Mar 2012 | - | -$5.16 M(+112.8%) | -$12.45 M(+28.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$9.72 M(+41.1%) | -$2.42 M(-13.1%) | -$9.72 M(+5.2%) |
| Sept 2011 | - | -$2.79 M(+34.6%) | -$9.24 M(+5.8%) |
| June 2011 | - | -$2.07 M(-14.8%) | -$8.73 M(+7.6%) |
| Mar 2011 | - | -$2.43 M(+25.4%) | -$8.11 M(+17.8%) |
| Dec 2010 | -$6.89 M(+104.8%) | -$1.94 M(-15.0%) | -$6.89 M(+3.0%) |
| Sept 2010 | - | -$2.28 M(+56.6%) | -$6.69 M(+17.8%) |
| June 2010 | - | -$1.46 M(+20.7%) | -$5.68 M(+7.4%) |
| Mar 2010 | - | -$1.21 M(-30.7%) | -$5.29 M(+57.3%) |
| Dec 2009 | -$3.36 M(+24.0%) | -$1.74 M(+36.9%) | -$3.36 M(-526.0%) |
| Sept 2009 | - | -$1.27 M(+19.1%) | $789.50 K(+507.3%) |
| June 2009 | - | -$1.07 M(-248.4%) | $130.00 K(-115.1%) |
| Mar 2009 | - | $720.10 K(-70.1%) | -$863.20 K(-68.2%) |
| Dec 2008 | -$2.71 M(-58.8%) | $2.41 M(-224.8%) | -$2.71 M(-50.5%) |
| Sept 2008 | - | -$1.93 M(-6.3%) | -$5.48 M(-11.2%) |
| June 2008 | - | -$2.06 M(+82.6%) | -$6.18 M(-0.0%) |
| Mar 2008 | - | -$1.13 M(+213.0%) | -$6.18 M(-6.2%) |
| Dec 2007 | -$6.59 M(-1.2%) | -$360.70 K(-86.3%) | -$6.59 M(-14.4%) |
| Sept 2007 | - | -$2.63 M(+27.3%) | -$7.70 M(+32.3%) |
| June 2007 | - | -$2.06 M(+34.0%) | -$5.81 M(+6.3%) |
| Mar 2007 | - | -$1.54 M(+4.8%) | -$5.47 M(-18.0%) |
| Dec 2006 | -$6.67 M(-32.2%) | -$1.47 M(+97.1%) | -$6.67 M(-20.0%) |
| Sept 2006 | - | -$744.70 K(-56.6%) | -$8.33 M(+20.6%) |
| June 2006 | - | -$1.72 M(-37.3%) | -$6.91 M(-20.4%) |
| Mar 2006 | - | -$2.74 M(-12.5%) | -$8.67 M(-11.8%) |
| Dec 2005 | -$9.84 M(-35.4%) | -$3.13 M(-561.4%) | -$9.84 M(-3.2%) |
| Sept 2005 | - | $678.50 K(-119.5%) | -$10.16 M(-34.5%) |
| June 2005 | - | -$3.48 M(-10.7%) | -$15.51 M(+3.4%) |
| Mar 2005 | - | -$3.90 M(+12.8%) | -$15.00 M(-1.5%) |
| Dec 2004 | -$15.23 M(-2.0%) | -$3.46 M(-25.9%) | -$15.23 M(-2.5%) |
| Sept 2004 | - | -$4.67 M(+56.9%) | -$15.62 M(+11.2%) |
| June 2004 | - | -$2.97 M(-27.9%) | -$14.05 M(-14.7%) |
| Mar 2004 | - | -$4.13 M(+7.2%) | -$16.48 M(+6.0%) |
| Dec 2003 | -$15.55 M(-33.1%) | -$3.85 M(+24.4%) | -$15.55 M(-1.8%) |
| Sept 2003 | - | -$3.10 M(-42.7%) | -$15.83 M(-18.5%) |
| June 2003 | - | -$5.40 M(+69.0%) | -$19.43 M(-6.3%) |
| Mar 2003 | - | -$3.20 M(-22.7%) | -$20.74 M(-10.7%) |
| Dec 2002 | -$23.23 M(+64.4%) | -$4.13 M(-38.3%) | -$23.23 M(-1.8%) |
| Sept 2002 | - | -$6.70 M(-0.1%) | -$23.65 M(+16.9%) |
| June 2002 | - | -$6.71 M(+17.8%) | -$20.23 M(+21.6%) |
| Mar 2002 | - | -$5.69 M(+24.9%) | -$16.64 M(+17.7%) |
| Dec 2001 | -$14.14 M(+123.6%) | -$4.56 M(+39.3%) | -$14.14 M(+20.5%) |
| Sept 2001 | - | -$3.27 M(+4.9%) | -$11.73 M(+13.9%) |
| June 2001 | - | -$3.12 M(-2.3%) | -$10.30 M(+2.6%) |
| Mar 2001 | - | -$3.19 M(+48.5%) | -$10.03 M(+58.7%) |
| Dec 2000 | -$6.32 M(+40.5%) | -$2.15 M(+16.8%) | -$6.32 M(+51.5%) |
| Sept 2000 | - | -$1.84 M(-35.5%) | -$4.17 M(+78.8%) |
| June 2000 | - | -$2.85 M(-649.9%) | -$2.33 M(-549.9%) |
| Mar 2000 | - | $518.70 K | $518.70 K |
| Dec 1999 | -$4.50 M(-13.0%) | - | - |
| Dec 1998 | -$5.17 M(+69.7%) | - | - |
| Dec 1997 | -$3.05 M | - | - |
FAQ
- What is Seelos Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Seelos Therapeutics?
- What is Seelos Therapeutics annual CFO year-on-year change?
- What is Seelos Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Seelos Therapeutics?
- What is Seelos Therapeutics quarterly CFO year-on-year change?
- What is Seelos Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Seelos Therapeutics?
- What is Seelos Therapeutics TTM CFO year-on-year change?
What is Seelos Therapeutics annual cash flow from operations?
The current annual CFO of SEEL is -$23.91 M
What is the all time high annual CFO for Seelos Therapeutics?
Seelos Therapeutics all-time high annual cash flow from operations is -$2.71 M
What is Seelos Therapeutics annual CFO year-on-year change?
Over the past year, SEEL annual cash flow from operations has changed by +$37.69 M (+61.18%)
What is Seelos Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SEEL is -$972.00 K
What is the all time high quarterly CFO for Seelos Therapeutics?
Seelos Therapeutics all-time high quarterly cash flow from operations is $2.68 M
What is Seelos Therapeutics quarterly CFO year-on-year change?
Over the past year, SEEL quarterly cash flow from operations has changed by +$4.78 M (+83.09%)
What is Seelos Therapeutics TTM cash flow from operations?
The current TTM CFO of SEEL is -$13.27 M
What is the all time high TTM CFO for Seelos Therapeutics?
Seelos Therapeutics all-time high TTM cash flow from operations is $789.50 K
What is Seelos Therapeutics TTM CFO year-on-year change?
Over the past year, SEEL TTM cash flow from operations has changed by +$21.82 M (+62.17%)